Unified clinical trial software
Unified clinical trial software for endocrinology clinical trials
oomnia unifies all clinical workflows for endocrinology studies, supporting precise management of long‑term metabolic, hormonal, and biomarker data across the study lifecycle
INDUSTRY CONTEXT
Why endocrinology trials are hard to run
Endocrinology trials are challenging due to long study durations, complex biomarker assessments, and the need to manage heterogeneous patient populations across extended follow‑up periods
Key challenges include:
Long study timelines driven by chronic and lifelong disease management
Patients respond very differently to treatment, so studies need more participants and careful grouping
Complex regulatory and safety requirements for hormone‑based therapies
Operational burden of sustained site engagement and consistent data quality over time
UNIFIED PLATFORM
Why unified clinical trial software is critical for endocrinology trials
Endocrinology trials involve chronic conditions, frequent laboratory testing, and variable hormone and metabolic biomarkers, often managed across multiple systems, resulting in fragmented data and increased site burden
A unified clinical trial platform built as a Clinical Research Information System (CRIS) brings endocrine‑specific data and processes into a single environment designed for longitudinal studies. This approach supports consistent data collection over time, improves oversight of hormonal and metabolic trends, and reduces operational strain across extended endocrinology programs.
| Area | Modular eClinical system | Unified clinical trial software (oomnia) |
|---|---|---|
| Data sources | Clinical data, laboratory results, biomarkers, and PROs managed in separate systems | All endocrine‑relevant data managed within one unified platform |
| Laboratory data management | Disconnected handling of central and local lab data and reference ranges | Integrated hormone and metabolic lab data with consistent reference range management |
| Longitudinal consistency | Data drift and variability over years of follow‑up | Consistent data structure maintained across extended study timelines |
| Reconciliation effort | Ongoing manual reconciliation of clinical and laboratory datasets | Reduced reconciliation through a shared, unified data model |
| Protocol evolution | Disruptive updates requiring rework across systems | Configuration‑based updates without interrupting ongoing follow‑up |
| Patient follow-up | Limited visibility into trends across repeated assessments | Continuous tracking of longitudinal endocrine outcomes |
| Site burden | High operational load from multiple tools and repeated data entry | Simplified site workflows within a single interface |
| Data quality | Increased risk of missing or inconsistent data over long studies | Structured capture with real‑time validation |
| Oversight | Delayed insight into safety and metabolic trends | Real‑time oversight across clinical and laboratory data |
| Scalability | Difficult to sustain multi‑year, multi‑site studies | Scales effectively across global, long‑duration endocrinology trials |
CRIS ARCHITECTURE
One unified platform for endocrinology trials
oomnia is designed to meet the long‑term, data‑intensive demands of endocrinology studies, from repeated laboratory assessments to evolving protocol requirements
Connects clinical data, laboratory results, and biomarker data at the patient level within a single system
Supports frequent assessments and protocol changes without disrupting ongoing studies
Reduces site and operational burden by replacing fragmented tools with a connected workflow
Maintains data quality and oversight across extended study timelines
ECOSYSTEM INTEGRATION
How oomnia supports the end‑to‑end endocrinology study environment
oomnia provides a centralized environment that brings together the data sources and stakeholders required to run long‑term, biomarker‑driven endocrinology studies efficiently and consistently
It integrates:
KEY CAPABILITIES
Key capabilities for endocrinology studies
Trial design and adaptation
- Supports endocrinology study designs characterized by long follow‑up periods, repeated assessments, and complex visit schedules
- Enables efficient configuration updates as eligibility criteria, endpoints, or assessment frequency evolve during chronic disease studies
- Maintains continuity of data collection during protocol amendments without interrupting ongoing participant follow‑up
Data capture and quality
- Enables real‑time data capture and validation across longitudinal endocrine datasets, including clinical, laboratory, and outcome data
- Provides a unified data flow across EDC, CTMS, RTSM, ePRO/eCOA, eTMF, eSource, and eConsent to support sustained study conduct
- Reduces manual reconciliation by maintaining consistent data structures across study systems
Long‑term patient adherence and reporting
- Supports flexible ePRO/eCOA for symptom tracking, treatment adherence, and quality‑of‑life assessment in chronic endocrine conditions
- Enables both remote and in‑clinic data capture to accommodate frequent visits and extended observation periods
- Automated visit and assessment reminders help reduce missed data points over long study durations
Oversight and analytics
- Provides consolidated dashboards combining clinical data with hormonal, metabolic, and laboratory results
- Supports ongoing safety surveillance, interim reviews, and trend analysis across extended endocrinology programs
- Generates submission‑ready outputs aligned with regulatory expectations (FDA, EMA, and global authorities)
Hormonal and metabolic laboratory data integration
- Integrates central and local laboratory data, including hormone levels and metabolic biomarkers, into a unified study view
- Aligns laboratory results directly with safety monitoring and data review workflows
- Enables comprehensive analysis by linking clinical outcomes with laboratory‑based endocrine endpoints
Purpose‑designed to support long‑term endocrinology programs involving chronic conditions, repeated assessments, and hormone‑based outcomes
Supports consistent tracking of hormonal and metabolic trends across long study timelines
Built on a unified data foundation that maintains consistency across clinical, laboratory, and patient‑reported data
Flexible configuration enables protocol updates and evolving assessment schedules
Simplifies daily operations for study sites, sponsors, and CROs managing sustained participant engagement and frequent data collection
Replaces fragmented study tools with a single platform tailored to the operational realities of endocrinology research
VALUE PROPOSITION
Why sponsors choose oomnia for endocrinology studies
Client Testimonials
Collaboration built on trust and innovation
Wemedoo's technology, expertise, and intimate engagement with our team in the development of the EDC, site/patient interface, and metric capabilities are unique. They provided insight and challenged the underlying assumptions to ensure the study's goals and objectives were clearly defined and the operating structure matched with the study's intent. Their system is not a one-size-fits-all and they adapt to the needs of the sponsor, sites, physicians, and the study requirements into a system that merges health information/data and can then become not only informative but actionable.
James Kuras
Vice President of Clinical Affairs and Operations at Centinel Spine
Wemedoo's cross-functional, integrated teams capture EDC set-up, go-live, data capture, data cleaning, and finally data analysis in a globally compliant fashion supporting trials in different geographies including the US. Their speed of addressing customer needs sets in my personal experience industry benchmark whilst keeping these data solutions lean and affordable. Besides the great proprietary systems they use, their integrated team approach with personal responsibility and honest commitment to targeting outcomes differentiates the Wemedoo team from other providers. Wemedoo only made Oxular's key initial trial, a device-drug trial possible, as based on some pre-work, the Wemedoo team could substantially adapt and update the first EDC ideas for a trial under a US FDA IND. The Wemedoo team worked extremely focused on familiarizing US trial sites and clinical CROs with the use of their system, which turned out to be a key success factor of the respective trial. The highly professional and up-to-date capabilities in data sciences were mirrored by customer-centricity and super fast timelines of integrating mandatory adaptations to the data systems.
Friedrich Asmus
Former Chief Medical Officer at OXULAR
All jobs, both large and small, are performed with the same dedication to quality, detail, innovative thinking, and rigor. It is always a pleasure to work with the Wemedoo team.
Georg Mathis, PhD
CEO at Appletree CI Group AG
Wemedoo embodies all the traits desired in a partner in the clinical trial industry – expertise, innovation, reliability, compliance, and attention to detail.
Martina Diminic Smetisko, DMD
Managing Director at Marti Farm Ltd
Their dedication to, and support of, our projects has resulted in clear quality deliverables. They are always there to answer any questions with expertise in a timely manner. I am looking forward to our next project together.
Volodymyr Stus, MD
Biopharmaceutics and Clinical Research Department Manager at Polpharma SA
Complex adaptive trials demand speed, precision, and system stability. With oomnia, Wemedoo's unified clinical trial software maintained continuous drug supply oversight, real-time data capture above 99%, and zero Randomization and Trial Supply Management (RTSM) dispensing errors throughout the study. The study reached database lock within 3 days after Last Patient Last Visit (LPLV), a direct result of integrated EDC–RTSM execution and proactive technical support. Wemedoo's technology and team responsiveness played a key role in meeting aggressive milestones.
Dhiraj Patel, Dr.
Director at Velocious Clinical Research
REGULATORY READINESS
Regulatory and data ecosystem readiness
oomnia supports endocrinology studies with a structured data environment built to meet global regulatory expectations for long‑term, hormone‑ and metabolism‑focused clinical studies
21 CFR Part 11 compliance
21 CFR Part 11–compliant electronic records, including audit trails and controlled electronic approvals
Risk-based quality management
Risk‑based quality practices aligned with ICH E6(R3), designed for prolonged study conduct and continuous oversight
CDISC-aligned data standards
Data collection and downstream outputs aligned with CDISC principles, supporting standardized endocrine data review and submission workflows
Global regulatory support
Regulatory submissions supported to FDA, EMA, and other global health authorities for endocrinology and metabolic indications
Get Started
Managing complex hormone and metabolic data over years of follow‑up?
See how oomnia supports endocrinology trials with a single platform built for chronic studies and repeated assessments
Talk to our team